Dexcom Continuous Glucose Monitoring in Long-term Care

Completed · Not applicable

Conditions studied: Diabetes, Diabetes Mellitus, Type 2

In brief

The goal of this study is to determine whether the use of Dexcom Continuous Glucose Monitoring with Glucose Telemetry System (CGM-GTS) with hypoglycemia alarm will facilitate diabetes treatment and reduce the risk of hypoglycemia in insulin and non-insulin treated patients with type 2 diabetes (T2D) in long-term care facilities, when compared to standard of care using capillary point of care testing.

Key facts

Study ID

NCT04818242

Run by

Emory University

People needed

100

Starts

2021-04-19

Expected to finish

2022-10-21

Last updated by the study team

2023-11-13

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Males and females admitted to subacute and long-term skilled nursing care facilities.
• Known history of T2D treated with insulin or insulin secretagogues with or without additional oral antidiabetic agents, short- and long-acting glucagon-like peptide-1 receptor agonists (GLP-1 RA).
• Patients with an expected long-term care facility length-of-stay > 1 week.

You may not qualify if…

• Patients expected to require MRI procedures during admission.
• Patients with clinically relevant hepatic disease (diagnosed liver cirrhosis and portal hypertension), corticosteroid therapy, end-stage renal disease (dialysis), or anasarca (massive peripheral edema).
• Female subjects who are pregnant or breast-feeding at time of enrollment into the study.

Where it is running

• A.G. Rhodes — Atlanta, Georgia, United States
• Emory Wesley Woods Hospital — Atlanta, Georgia, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.